The Pain Management Market Outlook To 2014: Competitive landscape, pipeline analysis and growth opportunities

Published by: Business Insights

Published: Jun. 22, 2009 - 221 Pages

Table of Contents

The Pain Management Market Outlook to 2014

Executive Summary

Overview and epidemiology of pain

Global market analysis

Pipeline analysis

Competitive landscape

Chapter 1 Scope and methodology

Scope

Methodology

Chapter 2 Overview and epidemiology of pain

Summary

Introduction

Neuropathic pain

Lower back pain

Background

Diagnosis, treatment and management

Epidemiology

Neuralgia/fibromyalgia

Background

Diagnosis, treatment and management

Epidemiology

Diabetic neuropathic pain

Background

Diagnosis, treatment and management

Epidemiology

Pain associated with multiple sclerosis

Background

Diagnosis, treatment and management

Epidemiology

Nociceptive pain

Arthritic pain

Background

Diagnosis, treatment and management

Epidemiology

Post-operative pain

Background

Diagnosis, treatment and management

Epidemiology

Cancer-related pain

Background

Diagnosis, treatment and management

Epidemiology

HIV/AIDS-related pain

Background

Diagnosis, treatment and management

Epidemiology

Chapter 3 Global market analysis

Summary

Introduction

Key events

Revival of Mundipharma’s OxyContin CR sales followin out-ofcourt settlements

Mylan’s fentanyl patches may succeed where J&J’s Duragesic failed

OGD loosens requirements for generic lidocaine patches

M&A and licensing deals to drive the global pain management market

Regional dynamics

Market analysis by drug class

Leading brands in the global pain market

Analgesics

Analgesics market analysis by drug class

Leading brands in the analgesics market

Leading players in the analgesics market

Analgesic drug classes

Narcotic analgesics

Non-narcotic analgesics

Analgesics sales forecasts

Anticonvulsants

Leading brands in the anticonvulsants market

Leading players in the anticonvulsants market

Anticonvulsants sales forecasts

Non-steroidal anti-inflammatory drugs

NSAIDs market analysis by drug class

Leading brands in the NSAIDs market

Leading players in the NSAIDs market

NSAID classes

Anti-rheumatic NSAIDs

Coxibs

NSAIDs sales forecasts

Local anesthetics

Local anesthetics market analysis by medical applications

Leading brands in the local anesthetics market

Leading players in the local anesthetics market

Local anesthetics sales forecasts

Global pain management sales forecasts

Chapter 4 Pipeline analysis

Summary

Introduction

R&D trends

Reduced R&D activity from leading drug companies

Innovative drug delivery formulations and reformulations

Development of products associated with better side effect profiles

Flexibility in titration and dosing

Entry of biologics into the pain management space

Trial data bridging may reduce the number of studies required for

EU approval

Leading products in development

New chemical entities

Tapentadol

Tanezumab

Naproxcinod

Ralfinamide

Novel formulations

Remoxy

Embeda

Onsolis

Diractin

Rapinyl/Abstral

Eladur

Pipeline sales forecasts

Chapter 5 Competitive landscape

Summary

Introduction

Sales performance of leading players

Forecast sales performance of the leading players

Pfizer

Overview

Drug class focus

Key brands

Pipeline portfolio

Strategic and growth analysis

J&J

Overview

Drug class focus

Key brands

Pipeline portfolio

Strategic and growth analysis

Novartis

Overview

Drug class focus

Key brands

Strategic and growth analysis

GlaxoSmithKline

Overview

Drug class focus

Key brands

Strategic and growth analysis

Mundipharma

Overview

Drug class focus

Key brands

Strategic and growth analysis

Abbott

Overview

Drug class focus

Key brands

Strategic and growth analysis

Sanofi-Aventis

Overview

Drug class focus

Key brands

Strategic and growth analysis

UCB

Overview

Drug class focus

Key brands

Strategic and growth analysis

Teva

Overview

Drug class focus

Key brands

Strategic and growth analysis

Endo Pharma

Overview

Drug class focus

Licensing deals

Key brands

Strategic and growth analysis

Chapter 6 Appendix

IMS Data

M1A1 Antirheumatics non-steroidal plain

M1A2 Antirheumatics non-steroidal combination

M1A3 Coxibs plain

N1B1 Anesthetics local medical injection

N1B2 Anaesthetics local dental injection

N1B3 Anaesthetics local topical

N1B9 Anaesthetics local others

N2A0 Narcotic analgesics

N2B0 Non-narcotic analgesics

N2B1 Non-narcotic analgesics, prescription

N2B2 Non-narcotic analgesics, OTC

N3A0 Anti-epileptics

Glossary

Index

List of Figures

Figure 2.1: Factors involved in pain sensation

Figure 3.2: Regional shares (%) of the pain management market, 2007

Figure 3.3: Clinical profile of OxyContin CR

Figure 3.4: Clinical profile of Duragesic

Figure 3.5: Clinical profile of Topamax

Figure 3.6: Clinical profile of Lamictal

Figure 3.7: Clinical profile of Lyrica

Figure 3.8: Clinical profile of Voltaren

Figure 3.9: Clinical profile of Celebrex

Figure 3.10: Clinical profile of Lidoderm

Figure 4.11: Leading recently launched products and late-stage R&D compounds indicated for the treatment of pain, 2009

Figure 4.12: “Abuse-deterrent” formulation design of Embeda

Figure 5.13: Market dynamics of leading players in the global pain management market, 2006-07

List of Tables

Table 2.1: Estimated prevalence of neuropathic and nociceptive pain in the seven major pharmaceutical markets, 2008

Table 2.2: Estimated prevalence of neuropathic lower back pain in the seven major pharmaceutical markets, 2008

Table 2.3: Forecast prevalence of neuropathic lower back pain across the seven major markets, 2008-14

Table 2.4: Estimated prevalence of neuralgia/fibromyalgia pain in the seven major pharmaceutical markets, 2008

Table 2.5: Forecast prevalence of neuralgia/fibromyalgia across the seven major markets, 2008- 14

Table 2.6: Estimated prevalence of diabetic neuropathic pain in the seven major pharmaceutical markets, 2008

Table 2.7: Forecast prevalence of diabetic neuropathic pain across the seven major markets, 2008-14

Table 2.8: Estimated prevalence of multiple sclerosis in the seven major pharmaceutical markets, 2008

Table 2.9: Forecast prevalence of pain associated with multiple sclerosis across the seven major markets, 2008-14

Table 2.10: Estimated prevalence of OA-related pain in the seven major pharmaceutical markets, 2008

Table 2.11: Estimated prevalence of RA pain in the seven major pharmaceutical markets, 2008

Table 2.12: Forecast prevalence of OA-related pain across the seven major markets, 2008-14

Table 2.13: Forecast prevalence of RA-related pain across the seven major markets, 2008-14

Table 2.14: Estimated prevalence of post-operative pain in the seven major pharmaceutical markets, 2008

Table 2.15: Forecast prevalence of post-operative pain across the seven major markets, 2008-14

Table 2.16: Estimated prevalence of cancer-related pain in the seven major pharmaceutical markets, 2008

Table 2.17: Forecast prevalence of early-stage cancer-related pain across the seven major markets, 2008-14

Table 2.18: Forecast prevalence of late-stage cancer-related pain across the seven major markets, 2008-14

Table 2.19: Estimated prevalence of HIV/AIDS-related neuropathic pain in the seven major pharmaceutical markets, 2008

Table 2.20: Forecast prevalence of HIV/AIDS-related pain across the seven major markets, 2008- 14

Table 3.21: Licensing deals in the global pain management market

Table 3.22: Break-up of the global pain management market by drug class, 2006-07

Table 3.23: Leading brands in the global pain management market, 2006-07

Table 3.24: Drug classes in the global analgesics market, 2006-07

Table 3.25: Leading brands in the global analgesics market, 2006-07

Table 3.26: Leading players in the global analgesics market, 2006-07

Table 3.27: Leading brands in the global narcotic analgesics market, 2006-07

Table 3.28: Leading brands in the global non-narcotic analgesics market, 2006-07

Table 3.29: Competitive analysis of Tylenol and Efferalgan

Table 3.30: Sales forecasts of analgesics, 2007-14

Table 3.31: Leading brands in the global anticonvulsants market, 2006-07

Table 3.32: Leading anticonvulsant brands based on proportion of sales generated by prescriptions for pain indications in the seven major markets, 2007

Table 3.33: Leading players in the global anticonvulsants market, 2006-07

Table 3.34: Sales forecast for the anticonvulsants, 2007-14

Table 3.35: Drug classes in the global NSAIDs market, 2006-07

Table 3.36: Leading brands in the global NSAIDs market, 2006-07

Table 3.37: Leading players in the global NSAIDs market, 2006-07

Table 3.38: Leading brands in the global anti-rheumatic NSAIDs market, 2006-07

Table 3.39: Leading brands in the global coxibs market, 2006-07

Table 3.40: Sales forecasts of NSAIDs, 2007-14

Table 3.41: Medical applications in the global local anesthetics market, 2006-07

Table 3.42: Leading brands in the global local anesthetics market, 2006-07

Table 3.43: Leading players in the global local anesthetics market, 2006-07

Table 3.44: Sales forecasts of local anesthetics, 2007-14

Table 3.45: Sales forecasts of the global pain management market, 2007-14

Table 4.46: An overview of tapentadol

Table 4.47: An overview of tanezumab

Table 4.48: An overview of naproxcinod

Table 4.49: An overview of ralfinamide

Table 4.50: An overview of Remoxy

Table 4.51: An overview of Embeda

Table 4.52: An overview of Onsolis

Table 4.53: An overview of Diractin

Table 4.54: An overview of Rapinyl/Abstral

Table 4.55: An overview of Eladur

Table 4.56: Sales forecasts of pipeline compounds, 2007-14

Table 5.57: Leading companies in the global pain management market,

Table 5.58: Pain management sales forecasts of the leading players in the market, 2007-14

Table 5.59: Pfizer’s pain management sales break-up based on drug class, 2007

Table 5.60: Pfizer’s leading pain management products, 2006-07

Table 5.61: Pfizer’s key pain management products under development, March 2009

Table 5.62: J&J’s pain management sales break-up based on drug class, 2007

Table 5.63: J&J’s leading pain management products, 2006-07

Table 5.64: J&J’s key pain management products under development,

Table 5.65: Novartis's pain management sales break-up based on drug class, 2007

Table 5.66: Novartis's leading pain management products, 2006-07

Table 5.67: GSK’s pain management sales break-up based on drug class, 2007

Table 5.68: GSK’s leading pain management products, 2006-07

Table 5.69: Mundipharma’s pain management sales break-up based on drug class, 2007

Table 5.70: Mundipharma’s leading pain management products, 2006-07

Table 5.71: Abbott’s pain management sales break-up based on drug class, 2007

Table 5.72: Abbott’s leading pain management products, 2006-07

Table 5.73: Sanofi-Aventis's pain management sales break-up based on drug class, 2007

Table 5.74: Sanofi-Aventis's leading pain management products, 2006-07

Table 5.75: UCB’s pain management sales break-up based on drug class, 2007

Table 5.76: UCB’s leading pain management products, 2006-07

Table 5.77: Teva’s pain management sales break-up based on drug class, 2007

Table 5.78: Teva’s leading pain management products, 2006-07

Table 5.79: Endo’s pain management sales break-up based on drug class, 2007

Table 5.80: Endo’s US pain management marketing licensing deals

Table 5.81: Endo’s leading pain management products, 2006-

Abstract

• The global pain management market generated $46.4bn sales in 2007, a 12.5% increase over 2006.
The most prevalent forms of neuropathic pain in the seven major markets were neuralgia/fibromyalgia and lower back pain, with 16.3m and 15.9m cases respectively during 2008.
• Analgesics (narcotics and non-narcotics) account for 43% of the global pain management market,
having generated revenues of $19.9bn in 2007. The segment also demonstrated robust 15.2% growth y-o-y.Narcotics segment is dominated by Mundipharma’s OxyContin CR, while the highly fragmented non-narcotic segment is led by BMS’ Efferalgan and J&J’s Tylenol.
• Pfizer was the leading player in the pain management market in 2007 with sales of $5.5bn, a 14.6% increase over 2006. Celebrex registered sales of
• Orexo AB's and Prostraken’s Rapinyl/Abstra and King's and Durect’s Eladur are the most promising
advanced formulations to recently enter Phase III trials. Rapinyl/Abstral is intended for breakthroughcancer pain and Eladur is the first bupivacaine formulation to receive orphan status from the FDA.

• Assess patient potential, treatment trends and sales patterns of major pain indications
over the period 2008-14, with this report’s coverage of neuropathic and nociceptive pain sub-categories across Japan, France, Germany, Italy, Spain, the UK and the US.
• Understand the market dynamics of the global pain management market with this report’s analysis of major drug classes and regional trends, and understand the impact of recent events by assessing key market issues and growth drivers.
• Compare the market performance and strategic positioning of major pharma companies’ pain management portfolios as of H1 2008 with this report’s evaluation of the franchises of Pfizer, J&J, Novartis, GSK Mundipharma, Abbott, Sanofi-Aventis, UCB, Teva and Endo Pharma.
• Forecast sales for key currently marketed pain management therapies as well as leading pipeline products over the period 2008-14, assess the latest trends influencing R&D and evaluate leading developmental products and new chemical entities. $2.3bn, followed by Lyrica with $1.9bn. Together these brands accounted for 75.5% of Pfizer’s overall sales in 2007.

• What will be the major growth indications in the pain management market over 2009-14?
• What are the current trends within the major therapy areas of neuropathic and nociceptive pain across the seven major markets?
• What are the most promising compounds currently in clinical development for major pain indications?
• What is the forecast commercial potential of these products through to 2014?
• Which companies are best positioned to succeed in the pain management market over 2009-14?
• What is the forecast market size and growth rate over the period 2009-14 across the pain management market?
• What are the significant market and pipeline developments that may shape the corporate strategies of leading companies?

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.